
CLAIMS

1. A therapeutic combination which comprises a B-Raf inhibitor of Formula (I)



(I), and

a second inhibitor which is a PI3 kinase inhibitor of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound F) or (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) (Compound X), or a pharmaceutically acceptable salt thereof, for separate, simultaneous or sequential administration.

2. The therapeutic combination according to claim 1 for use in the treatment of cancer.

3. The therapeutic combination according claim 2, wherein the cancer is characterized by a V600 mutation in B-Raf.

4. The therapeutic combination according to claim 2 or claim 3, wherein the cancer is melanoma characterized by a V600 mutation in B-Raf.

5. Use of a therapeutic combination according to claim 1 for the preparation of a pharmaceutical composition or medicament for the treatment of cancer characterized by a V600 mutation in B-Raf.

6. The use according to claim 5, wherein the cancer is melanoma characterized by a V600 mutation in B-Raf.

7. The therapeutic combination of claim 1, wherein the PI3 kinase inhibitor is 5-(2,6-di-morpholin-4-yl-pyrimidin-4-y1)-4-trifluoromethyl-pyridin-2-ylamine (Compound F), or a pharmaceutically acceptable salt thereof.

8. The therapeutic combination of claim 1, wherein the PI3 kinase inhibitor is (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) (Compound X), or a pharmaceutically acceptable salt thereof.

9. The therapeutic combination according to claim 2 or claim 3, wherein the cancer is colorectal cancer characterized by a V600 mutation in B-Raf.

10. The use according to claim 5, wherein the cancer is colorectal cancer characterized by a V600 mutation in B-Raf.